Randomized controlled trialHumanClinical Trial, Phase III
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
Nature medicine, 2026 Jul. Aronne LJ, Horn DB, le Roux CW and 11 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Nature medicine
Published
2026 Jul
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
HumansDouble-Blind MethodWeight LossSemaglutideObesityFemaleMaleMiddle AgedTirzepatideAdultGlucagon-Like PeptidesOxadiazoles
Other papers on Orforglipron
Randomized controlled trial · 2026
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
Randomized controlled trial · 2026Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial
Randomized controlled trial · 2025Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Randomized controlled trial · 2025Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Randomized controlled trial · 2023Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Randomized controlled trial · 2023Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page